Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 3/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | YES1 | P07947 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725718 | 0.85 | MAP3K5 (0.43) | BTKSYKCLK2TYK2MAP3K5 | |
| SCHEMBL1725921 | 0.85 | BTK (0.38) | BTKSYKCLK2MAP3K5 | |
| SCHEMBL1726136 | 0.81 | BTK (0.36) | BTKSYKCLK2MAP3K5 | |
| SCHEMBL1725492 | 0.81 | BTK (0.40) | BTKCLK2MAP3K5 | |
| SCHEMBL1724583 | 0.81 | BTK (0.39) | BTKSYKCLK2MAP3K5 | |
| SCHEMBL12602969 | 0.78 | BTK (0.46) | BTKTYK2 | |
| SCHEMBL14933856 | 0.77 | BTK (0.35) | BTKCLK2 | |
| SCHEMBL10255868 | 0.77 | MAPK14 (0.47) | BTKPIK3CAPRKDCTYK2 | |
| SCHEMBL1725758 | 0.77 | BTK (0.39) | BTKPIK3CAPRKDCTYK2MTOR | |
| SCHEMBL13139759 | 0.76 | CA12 (0.38) | BTKPIK3CAPRKDCSYKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773632-B1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-8754077-B2 | 8-fluorophthalazin-1(2H)-one compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8754077-B2 | 8-fluorophthalazin-1(2H)-one compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2013067264-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | BTK 1/4885PIK3CA 185/4885PRKDC 112/4885 |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | BTK 1/4885PIK3CA 173/4885PRKDC 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.